UCI Beall **Applied Innovation**

Research Translation Group

Research Translation Group

Available Technologies

Contact Us

Permalink

Request Information

Nanoparticle Therapeutic Vaccines for Cancer **Treatment**

Tech ID: 33994 / UC Case 2025-764-0

BRIEF DESCRIPTION

A cutting-edge vaccine delivery platform that enhances tumor treatment by co-delivering MHC class I and II restricted antigens.

FULL DESCRIPTION

This technology represents a novel approach in the field of immunotherapy, specifically designed to combat aggressive cancers such as melanoma and colon carcinoma. By utilizing nanoparticles to simultaneously deliver both MHC class I and II restricted tumor antigens, this platform aims to induce a more potent and specific anti-tumor immune response. This method addresses the limitations of current cancer treatments by focusing on the activation and persistence of cytotoxic T cells, thereby offering a promising strategy for the treatment of persistent cancers.

SUGGESTED USES

» Development of more effective cancer vaccines targeting both major T cell subsets for the treatment of melanoma and other aggressive cancers.

» Advancement in immunotherapy approaches by providing a more targeted and sustained anti-tumor immune response.

» Potential for application in a wide range of cancer types, due to the universal strategy of targeting MHC class I and II restricted antigens.

ADVANTAGES

» Improves anti-tumor immune response through co-delivery of MHC class I and II melanoma tumorassociated antigens.

» Enhances treatment efficacy over single-antigen nanoparticles by simultaneously delivering both MHC classes of tumor-associated antigens, demonstrating the importance of dual-antigen design.

» Alleviates severe side-effects associated with current cancer therapies such as radioactive therapy.

PATENT STATUS

Patent Pending

CONTACT

Alvin Viray aviray@uci.edu tel: 949-824-3104.



OTHER INFORMATION

CATEGORIZED AS

- » Biotechnology
 - >>> Health
- » Medical

 - » Disease: Cancer
 - >>> Therapeutics
 - >> Vaccines
- » Nanotechnology » NanoBio
- >> Research Tools > Antibodies

RELATED CASES 2025-764-0



5270 California Avenue / Irvine,CA 92697-7700 / Tel: 949.824.2683



© 2025, The Regents of the University of California Terms of use Privacy Notice